Microbiota impacts on chronic inflammation and metabolic syndrome - related cognitive dysfunction
Cognitive dysfunction, one of the major concerns of increased life expectancy, is prevalent in patients with metabolic disorders. Added to the inflammation in the context of aging (inflammaging), low-grade chronic inflammation (metaflammation) accompanies metabolic diseases. Peripheral and central inflammation underlie metabolic syndrome - related cognitive dysfunction. The gut microbiota is increasingly recognized to be linked to both inflammaging and metaflammation in parallel to the pathophysiology of obesity, type 2 diabetes and the metabolic syndrome. Microbiota composition, diversity and diverse metabolites have been related to different metabolic features and cognitive traits. The study of different mouse models has contributed to identify characteristic microbiota profiles and shifts in the microbial gene richness in association with cognitive function. Diet, exercise and prebiotics, probiotics or symbiotics significantly influence cognition and changes in the microbiota. Few studies have analyzed the gut microbiota composition in association with cognitive function in humans. Impaired attention, mental flexibility and executive function have been observed in association with a microbiota ecosystem in cross-sectional and longitudinal studies. Nevertheless, the evidence in humans is still scarce and not causal relationships may be inferred, so larger and long-term studies are required to gain insight into the possible role of microbiota in human cognition.
KeywordsMicrobiota Cognitive dysfunction Low-grade inflammation Metabolic disorders
María Arnoriaga-Rodríguez is funded by a predoctoral “FIS” contract (PI16/02173) from the Instituto de Salud Carlos III, Spain.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
Research involving human participants and/or animals. Informed consent
No applicable. This work focused on previously published studies and no own new studies were undertook.
- 1.Institute for Health Metrics and Evaluation [IHME]. Findings from the global burden of disease study 2017. Seattle, WA: IHME; 2018.Google Scholar
- 2.GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years [DALYs] for 359 diseases and injuries and healthy life expectancy [HALE] for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Diseases Study 2017. Lancet. 2018;392:1859–1922.Google Scholar
- 4.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington DC; 2013.Google Scholar
- 19.Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2019; 10.1038/s41577-019-0198-4,Google Scholar
- 21.Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedGoogle Scholar
- 24.Pugazhenthi S, Qin L, Reddy PH. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s disease. Biochim Biophys Acta Mol basis Dis. 1863;2017:1037–45.Google Scholar
- 28.Walker JM, Dixit S, Saulsberry AC, May JM, Harrison FE. Reversal of high fat diet-induced obesity improves glucose tolerance, inflammatory response, β-amyloid accumulation and cognitive decline in the APP/PSEN1 mouse model of Alzheimer’s disease. Neurobiol Dis. 2017;100:87–98.PubMedPubMedCentralGoogle Scholar
- 31.Consolim-Colombo FM, Sangaleti CT, Costa FO, Morais TL, Lopes HF, Motta JM, et al. Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial. JCI Insight. 2017;2. pii: 93340.Google Scholar
- 34.O’Grady JP, Dean DC 3rd, Yang KL, Canda CM, Hoscheidt SM, Starks EJ, et al. Elevated insulin and insulin resistance are associated with altered myelin in cognitively unimpaired middle-aged adults. Obesity [SilverSpring]. 2019;27:1464–1471.Google Scholar
- 38.Cai D. Neuroinflammation and Neurodegeneration in overnutrition-induced diseases. Trend Endocrinol Metab. 2013;24:40–7.Google Scholar
- 54.Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.Google Scholar
- 60.Gao R, Zhu C, Li H, Yin M, Pan C, Huang L, et al. Dysbiosis signatures of gut microbiota along the sequence from healthy, young patients to those with overweight and obesity. Obesity (Silver Spring). 2018;26:351–61.Google Scholar
- 71.Li D, Ke Y, Zhan R, Liu C, Zhao M, Zeng A, et al. Trimethylamine-N-oxide promotes brain aging and cognitive impairment in mice. Aging Cell. 2018;49:e12768.Google Scholar
- 81.Marungruang N, Kovalenko T, Osadchenko I, Voss U, Huang F, Burleigh S, et al. Lingonberries and their two separated fractions differently alter the gut microbiota, improve metabolic functions, reduce gut inflammatory properties, and improve brain function in ApoE−/− mice fed high-fat diet. Nutr Neurosci. 2018:1–13.Google Scholar
- 82.López P, Sánchez M, Pérez-Cruz C, Velázquez-Villegas LA, Syeda T, Aguilar-López M, et al. Long-term genistein consumption modifies gut microbiota, improving glucose metabolism, metabolic endotoxemia, and cognitive function in mica fed a high-fat diet. Mol Nutr Food Res. 2018;62:e1800313.PubMedGoogle Scholar
- 84.Chunchai T, Thunapong W, Yasom S, Wanchai K, Eaimworawuthikul S, Metzler G, et al. Decreased microglial activation through gut-brain axis by prebiotics, probiotics, or symbiotics effectively restored cognitive function in obese-insulin resistant rats. J Neuroinflammation. 2018;15:11.PubMedPubMedCentralGoogle Scholar